You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

30 search results for: CRSwNP

Biologics in <b>CRSwNP</b>: Comparative Efficacy and Real-World Effectiveness

expert video

Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

10 min

Rhinology

Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.

Targeting Underlying Inflammation in <b>CRSwNP</b>, a Type 2 Inflammatory Disease

expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

10 min

Rhinology

Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.

<b>CRSwNP</b>: A Chronic Type 2 Inflammatory Disease

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

IRS-ISIAN 2024 | Remission in <b>CRSwNP</b>: A Real-World Perspective

expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

8 min

Rhinology

Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.

expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

20 min

Rhinology

Prof. Peter Hellings and Prof. Eugenio De Corso discuss viewpoints on the emerging definitions of disease remission in CRSwNP.

EAACI 2023 | Biologics in <b>CRSwNP</b>: Comparative Efficacy and Real-World Effectiveness

expert video

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

21 min

Rhinology

Join Profs. Martin Wagenmann and Eugenio De Corso as they discuss type 2 inflammation in CRSwNP and explore real-world data on biologic efficacy.

Clinical Management of <b>CRSwNP</b>: Maximizing Symptom Improvement

expert video

Clinical Management of CRSwNP: Maximizing Symptom Improvement

17 min

Rhinology

Prof. Fokkens presents recent evidence of biologic effectiveness for CRSwNP from the real-world setting

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in <b>CRSwNP</b>

expert video

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

42 min

Rhinology

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

Connecting Type 2 Inflammation to <b>CRSwNP</b>

expert video

Connecting Type 2 Inflammation to CRSwNP

1 min

Rhinology

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

Defining Mechanisms of Anosmia in <b>CRSwNP</b>

expert video

Defining Mechanisms of Anosmia in CRSwNP

2 min

Rhinology

Prof. Wytske Fokkens examines what is known and what else should be explored to understand the mechanisms of anosmia in patients with CRSwNP.

IRS-ISIAN 2024 | Mechanisms of Smell Loss in <b>CRSwNP</b>: Blockage and Inflammation

expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

10 min

Rhinology

Prof. Joaquim Mullol examines the mechanisms of smell loss in CRSwNP including the roles of conductive and sensorineural dysfunction.

<b>CRSwNP</b> Significantly Affects the Quality of Life of <b>CRSwNP</b> Patients

interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

10 min

Rhinology

Explore the factors that contribute to the significant burden of CRSwNP on patient quality of life.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region